Can Targeting the TCA Cycle Provide Therapeutic Benefits?
Targeting the altered TCA cycle in cancer cells offers a potential therapeutic strategy. Inhibitors of mutant IDH, for instance, have shown promise in treating certain types of cancer by reducing the levels of the oncometabolite 2-hydroxyglutarate. Additionally, drugs that impact the redox balance or the availability of TCA cycle intermediates can selectively kill cancer cells while sparing normal cells. Understanding the specific metabolic dependencies of different cancers can aid in the development of targeted therapies.
